

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 4173

HOUGHTON ET AL.

Examiner: Benjamin J. Packard

APPLICATION NO: 10/530,618

FILED: FEBRUARY 23, 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED
RESISTANCE TO THERAPEUTIC AGENTS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Office action of July 2, 2009, and in conjunction with the Petition to
Revive an Application Unintentionally Abandoned under 37 C.F.R. §1.137(b) submitted
herewith, please enter the following amendments into the above-identified application:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

Certificate of EFS-Web Transmission

I hereby certify that this correspondence is being transmitted to the U.S. Patent and Trademark Office via the Office's
electronic filing system on May 11, 2010.

Ann R. Pokalsky
(Printed Name)

Signature:

